ESR1 and neoplasm: The PLATO is a non-randomized, phase II, multi-center prospective clinical trial to increase the rate for breast conserving surgery (BCS) using a personalized neoadjuvant approach in ER+/HER2− women with BC with a measurable tumor size for whom BCS is not feasible.